Device Recall InnerVue Diagnostic Scope System 의 리콜

U.S. Food and Drug Administration에 따르면, 해당 리콜 는 United States 에서 Biomet, Inc. 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

의료기기에 문제가 생겼을 경우 제조사가 이를 바로잡거나 시장에서 회수하는 조치를 말한다. 회수(Recall)는 의료기기에 결함이 있거나, 건강에 위협이 되거나, 또는 결함도 있고 건강에도 위협이 될 경우에 발생한다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Recall
  • 사례 ID
    57965
  • 사례 위험등급
    Class 2
  • 사례 연번
    Z-1589-2011
  • 사례 시작날짜
    2011-02-10
  • 사례 출판 날짜
    2011-03-07
  • 사례 상황
    Terminated
  • 사례 국가
  • 사례 종료 날짜
    2013-08-27
  • 사례 출처
    USFDA
  • 사례 출처 URL
  • 비고 / 경고
    U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
    The Parent Company was added by ICIJ.
    The parent company information is based on 2017 public records.
  • 데이터 추가 비고
    laparoscope - Product Code HRX
  • 원인
    The cannula could not be connected to the scope and scopes disengage during use. the outer hub of innervue scopes may become detached from the inner hub of the scopes during assembly of the scope to the innervue hand piece. this condition may prevent the innervue scope from being securely attached to the innervue hand piece.
  • 조치
    On 2/10/2011, Biomet issued an "URGENT MEDICAL DEVICE NOTICE" to their Direct Accounts instructing customers to identify and discontinue use of the recalled products and return them to Biomet. Response forms were provided.

Device

  • 모델명 / 제조번호(시리얼번호)
    PART NUMBER 922141, LOT NUMBERS-649680, 818630, 390060, 968890, 783990, 784000
  • 의료기기 분류등급
  • 의료기기 등급
    2
  • 이식된 장치?
    No
  • 유통
    Distribution USA nationwide and to the Netherlands
  • 제품 설명
    Biomet INNERVUE DISPOSABLE SCOPE KIT 1.2MM WITH CANNULA SET, PRODUCT NUMBER 922141, STERILE
  • Manufacturer

Manufacturer

  • 제조사 주소
    Biomet, Inc., 56 E Bell Dr, Warsaw IN 46582
  • 제조사 모회사 (2017)
  • 제조사 의견
    “The safety of patients has always been, and continues to be, Zimmer Biomet’s top priority and it is our honor to be a leader in this industry for the past 90 years,” Zimmer Biomet told ICIJ in a statement. “We adhere to strict regulatory standards, and work closely with the FDA and all applicable regulatory agencies in each of our regions as part of our commitment to operating a first-rate quality management system across our global manufacturing network. The company added that it is focused on staying at the forefront of innovation and doing right by the millions of patients who rely on the company’s products.
  • Source
    USFDA